Last reviewed · How we verify
Zoledronic Acid 4 MG
At a glance
| Generic name | Zoledronic Acid 4 MG |
|---|---|
| Also known as | Zometa, Zometa®, ZOL, Zoledronate, Zoledronate acid |
| Sponsor | Assiut University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Zoledronic Acid Treatment in Patients With Congenital Dyserythropoietic Anemia (PHASE1, PHASE2)
- Comparing a Single-Dose vs. Twice Yearly Zoledronate in Patients With Early Stage Breast Cancer (REaCT-ZOL) (PHASE4)
- Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis (PHASE1, PHASE2)
- Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma (PHASE1)
- Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial (PHASE1)
- Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone (PHASE3)
- Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis 2 (ZOLARMAB2) (PHASE4)
- Zoledronic Acid for the Prevention of TDF-sparing ART-induced Bone Mass Density Loss in Treatment-naive HIV Positive Individuals (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zoledronic Acid 4 MG CI brief — competitive landscape report
- Zoledronic Acid 4 MG updates RSS · CI watch RSS
- Assiut University portfolio CI